The impact on the multidisciplinary team of molecular profiling for personalized therapy in non-small cell lung cancer-Reference-Cited by-同舟云学术

The impact on the multidisciplinary team of molecular profiling for personalized therapy in non-small cell lung cancer

Published:2013-02 Issue:2 Volume:79 Page:101-103
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Blackhall Fiona,Thatcher Nick,Booton Richard,Kerr Keith

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference5 articles.

1. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

2. Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC);Camidge;J Clin Oncol,2011

3. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization;Paik;J Thorac Oncol,2011

4. Revolution in lung cancer: new challenges for the surgical pathologist;Cagle;Arch Pathol Lab Med,2011

5. Personalized medicine for lung cancer: new challenges for pathology;Kerr;Histopathology,2012

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Accuracy of lung cancer staging in the multidisciplinary team setting;Translational Lung Cancer Research;2020-08

2. Patient perspectives on a national multidisciplinary team meeting for a rare cancer;European Journal of Cancer Care;2018-12-03

3. Organization of Lung Cancer Care;Lung Cancer: A Practical Approach to Evidence-Based Clinical Evaluation and Management;2018

4. Outcomes of cancer therapy administered to treatment-naïve lung cancer patients in the intensive care unit;Journal of Cancer;2017

5. Easily detectable cytomorphological features to evaluate during ROSE for rapid lung cancer diagnosis: from cytology to histology;Oncotarget;2016-11-08